查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153376

2026-2034年全球產前和新生兒基因檢測市場規模、佔有率、趨勢和成長分析報告

Global Prenatal And Newborn Genetic Testing Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 221 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球產前和新生兒基因檢測市場預計將從2025年的79.3億美元成長至2034年的219.7億美元，2026年至2034年的複合年成長率（CAGR）為11.99%。隨著醫療保健系統越來越重視在懷孕和出生後早期發現遺傳疾病，該市場正在不斷擴張。產前基因檢測有助於評估特定染色體異常和遺傳疾病的風險，而新生兒基因檢測則有助於早期發現可透過及時干預改善的疾病。人們對生殖健康的日益關注、篩檢技術的進步以及遺傳諮詢服務的普及，都在推動市場需求。非侵入性產前檢測也日益受到關注，因為它無需進行侵入性檢體採集，即可透過分析母體血液中循環的遊離胎兒DNA來篩檢特定的染色體異常。

市場成長主要得益於DNA定序、分子診斷和檢查室自動化技術的進步。醫療機構正擴大將基因篩檢納入產前護理和新生兒篩檢計畫（如適用）。公共衛生舉措的拓展、診斷基礎設施的完善以及公眾對遺傳疾病認知的提高也推動了基因篩檢的普及。診斷實驗室正投資於能夠更有效率地分析基因資訊的先進檢測平台。同時，醫療專業人員、生技公司和公共衛生機構之間日益密切的合作，正在加速開發更廣泛的檢測項目，並改善確診流程。

該市場的未來前景將取決於檢測準確性的提高、遺傳諮詢服務的普及以及更全面的篩檢方法的開發。定序技術的進步將有助於識別更多種類的遺傳疾病，而生物資訊學工具的改進則有助於更有效地解讀檢測結果。隨著篩檢項目和後續診斷服務的整合程度不斷提高，患者家庭將獲得適當的臨床指導。然而，倫理考量、隱私問題、服務取得方面的差異以及可能觀察情況觀察妥善處理。清晰的知情同意程序、臨床監督和負責任的溝通對於永續發展仍然至關重要。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球產前與新生兒基因檢測市場：依產品類型分類

  • 市場分析、洞察與預測
  • 消耗品
  • 裝置

第5章 全球產前與新生兒基因檢測市場：依篩檢類別分類

  • 市場分析、洞察與預測
  • 非侵入性產前檢測
  • 絨毛膜絨毛採樣
  • 羊膜穿刺術
  • 母體血清篩檢
  • 其他

第6章 全球產前與新生兒基因檢測市場：依疾病分類

  • 市場分析、洞察與預測
  • 唐氏症
  • 苯酮尿症
  • 囊腫纖維化
  • 鐮狀細胞貧血症
  • 其他

第7章 全球產前與新生兒基因檢測市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 婦產科和專科診所
  • 診斷中心

第8章 全球產前與新生兒基因檢測市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Natera
    • Illumina
    • Labcorp
    • Quest Diagnostics
    • Roche
    • Thermo Fisher Scientific
    • Fulgent Genetics
    • Invitae
    • Myriad Genetics
    • BillionToOne
    • BGI
    • Natera Panorama
    • Eurofins
    • PerkinElmer
    • Revvity
    • GeneTech
    • Ariosa Diagnostics
    • CooperSurgical
    • Yourgene Health
    • Centogene
簡介目錄
Product Code: VMR112111695

The global prenatal and newborn genetic testing market size is expected to reach USD 21.97 Billion in 2034 from USD 7.93 Billion in 2025, growing at a CAGR of 11.99% during 2026-2034.This market is expanding as healthcare systems place greater emphasis on early identification of genetic conditions during pregnancy and shortly after birth. Prenatal genetic testing can help assess the risk of selected chromosomal and inherited disorders, while newborn genetic testing supports the early detection of conditions that may benefit from timely intervention. Growing awareness of reproductive health, improvements in screening technologies, and increased availability of genetic counseling are supporting demand. Noninvasive prenatal testing has also attracted attention because it analyzes cell-free fetal DNA circulating in maternal blood to screen for certain chromosomal conditions without requiring an invasive sampling procedure.

Market growth is driven by advancements in DNA sequencing, molecular diagnostics, and laboratory automation. Healthcare providers are increasingly integrating genetic screening into prenatal care and newborn screening programs where appropriate. Expanding public health initiatives, improved diagnostic infrastructure, and rising awareness of inherited disorders are also contributing to adoption. Diagnostic laboratories are investing in advanced testing platforms that can analyze genetic information with improved efficiency. At the same time, growing collaboration among healthcare professionals, biotechnology companies, and public health organizations is supporting the development of broader testing panels and improved pathways for confirmatory diagnosis.

The future prospects of this market will be shaped by improvements in test accuracy, wider access to genetic counseling, and the development of more comprehensive screening approaches. Advances in sequencing technologies may enable the identification of a broader range of genetic conditions, while improved bioinformatics tools could support more efficient interpretation of results. Greater integration of screening programs with follow-up diagnostic services may help ensure that families receive appropriate clinical guidance. However, ethical considerations, privacy concerns, unequal access, and the potential for uncertain or incidental findings require careful management. Clear consent procedures, clinical oversight, and responsible communication will remain essential to sustainable growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product Type

  • Consumables
  • Instruments

By Screening

  • Non-Invasive Prenatal Testing
  • Chronic Villus Sampling
  • Amniocentesis
  • Maternal Serum Screening
  • Others

By Disease

  • Downs Syndrome
  • Phenylketonuria
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Others

By End User

  • Hospital
  • Maternity And Specialty Clinics
  • Diagnostic Centers

COMPANIES PROFILED

  • Natera, Illumina, Labcorp, Quest Diagnostics, Roche, Thermo Fisher Scientific, Fulgent Genetics, Invitae, Myriad Genetics, BillionToOne, BGI, Natera Panorama, Eurofins, PerkinElmer, Revvity, GeneTech, Ariosa Diagnostics, CooperSurgical, Yourgene Health, Centogene

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product Type
  • 4.2. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY SCREENING 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Screening
  • 5.2. Non-Invasive Prenatal Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Chronic Villus Sampling Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Amniocentesis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Maternal Serum Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY DISEASE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Disease
  • 6.2. Downs Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Phenylketonuria Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Cystic Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Sickle Cell Anemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY END USER 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End User
  • 7.2. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Maternity And Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Product Type
    • 8.2.2 By Screening
    • 8.2.3 By Disease
    • 8.2.4 By End User
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Product Type
    • 8.3.2 By Screening
    • 8.3.3 By Disease
    • 8.3.4 By End User
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Spain
    • 8.3.10 Russia
    • 8.3.11 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Product Type
    • 8.4.2 By Screening
    • 8.4.3 By Disease
    • 8.4.4 By End User
    • 8.4.5 China
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 India
    • 8.4.9 Australia
    • 8.4.10 South East Asia
    • 8.4.11 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Product Type
    • 8.5.2 By Screening
    • 8.5.3 By Disease
    • 8.5.4 By End User
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Product Type
    • 8.6.2 By Screening
    • 8.6.3 By Disease
    • 8.6.4 By End User
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PRENATAL AND NEWBORN GENETIC TESTING INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Natera
    • 10.2.2 Illumina
    • 10.2.3 Labcorp
    • 10.2.4 Quest Diagnostics
    • 10.2.5 Roche
    • 10.2.6 Thermo Fisher Scientific
    • 10.2.7 Fulgent Genetics
    • 10.2.8 Invitae
    • 10.2.9 Myriad Genetics
    • 10.2.10 BillionToOne
    • 10.2.11 BGI
    • 10.2.12 Natera Panorama
    • 10.2.13 Eurofins
    • 10.2.14 PerkinElmer
    • 10.2.15 Revvity
    • 10.2.16 GeneTech
    • 10.2.17 Ariosa Diagnostics
    • 10.2.18 CooperSurgical
    • 10.2.19 Yourgene Health
    • 10.2.20 Centogene